Piper Jaffray Remains Bearish on Bristol-Myers Squibb (BMY) Following Japan's Approval of Harvoni
Tweet Send to a Friend
Piper Jaffray maintains an Underweight rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) following Harvoni's approval in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
